Cytokinetics, Incorporated P/E Ratio 1999–2025
Cytokinetics, Incorporated reported 31.15 of price-to-earnings ratio for fiscal 2016. That was 2597.9% higher than fiscal 2009. Compared with fiscal 2009, the change was +2597.9%. This is a fiscal-year-end price divided by diluted EPS—not a live valuation—and is omitted when annual EPS is not positive.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | — | — |
| FY 2024 | — | — |
| FY 2023 | — | — |
| FY 2022 | — | — |
| FY 2021 | — | — |
| FY 2020 | — | — |
| FY 2019 | — | — |
| FY 2018 | — | — |
| FY 2017 | — | — |
| FY 2016 | 31.15 | — |
| FY 2015 | — | — |
| FY 2014 | — | — |
| FY 2013 | — | — |
| FY 2012 | — | — |
| FY 2011 | — | — |
| FY 2010 | — | — |
| FY 2009 | 1.15 | — |
| FY 2008 | — | — |
| FY 2007 | — | — |
| FY 2006 | — | — |
| FY 2005 | — | — |
| FY 2004 | — | — |
| FY 2003 | — | — |
| FY 2002 | — | — |
| FY 2001 | — | — |
| FY 2000 | — | — |
| FY 1999 | — | — |
Source: Cytokinetics, Incorporated SEC filings — fiscal-year-end price ÷ diluted EPS. Computed deterministically; refreshed nightly (last updated August 2, 2026). Open CYTK 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Cytokinetics, Incorporated reported 31.15 of price-to-earnings ratio for fiscal 2016. That was 2597.9% higher than fiscal 2009. Compared with fiscal 2009, the change was +2597.9%. This is a fiscal-year-end price divided by diluted EPS—not a live valuation—and is omitted when annual EPS is not positive. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Cytokinetics, Incorporated
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeCytokinetics, Incorporated — frequently asked questions
What is Cytokinetics, Incorporated's price-to-earnings ratio?
Cytokinetics, Incorporated (CYTK) reported price-to-earnings ratio of 31.15 for fiscal year 2016, per its SEC filings.
How has Cytokinetics, Incorporated's price-to-earnings ratio changed over time?
Between fiscal 1999 and 2025, CYTK's price-to-earnings ratio grew at roughly 13.5% per year (compound annual rate), from 1.15 to 31.15.
Where does this data come from?
Figures are computed from Cytokinetics, Incorporated's official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.
More CYTK financial history
Full CYTK fundamentals page → · Analyze price-to-earnings ratio with a free tool → · Research guide & leaders → · All 1,500+ companies →